Fluticasone furoate + Vilanterol

Form: Powder For Inhalation(DPI/MDI)

Strength: 92 mcg Fluticasone furoate / 22 mcg Vilanterol; 184 mcg Fluticasone furoate / 22 mcg Vilanterol

Reference Brands: Breo Ellipta®(US), Relvar Ellipta® (EU)

Category: Respiratory Disorder

Fluticasone furoate and Vilanterol is a powerful once-daily combination therapy used for the long-term treatment of asthma and chronic obstructive pulmonary disease (COPD). Marketed as Breo Ellipta® in the U.S. and Relvar Ellipta® in the EU, this inhalation powder combines Fluticasone, a corticosteroid that reduces inflammation, with Vilanterol, a long-acting beta-agonist (LABA) that relaxes airway muscles. Available in 92/22 mcg and 184/22 mcg strengths via the Ellipta® DPI, it offers 24-hour symptom control. Ideal for pharma B2B and export markets, this therapy enhances adherence and delivers effective respiratory relief with convenient once-daily dosing.